Introduction
============

Lung cancer is one of the most common cancers globally. An estimated 1.8 million new lung cancer cases occurred in 2012, accounting for \~13% of all cancer diagnoses. Lung cancer was the most frequently diagnosed cancer and the leading cause of cancer death for males and females in that same year ([@b1-ol-0-0-7047]). In less developed countries in Eastern Asia, including China, the incidence and mortality of lung cancer were higher than other cancer types in 2012 ([@b2-ol-0-0-7047]). The lung cancer burden has significantly increased in Hebei province, China, which is severely polluted, from 1973--1975 to 2010--2011, with a rate of increase of 189.15% ([@b3-ol-0-0-7047]). Other studies have proposed that outdoor pollution, which includes increasing concentrations of SO~2~ emissions, nitrogen oxide emissions or particulate matter 2.5, as well as an increase in smoking prevalence, has contributed to the increasing rate of lung cancer incidence ([@b4-ol-0-0-7047],[@b5-ol-0-0-7047]). According to a survey by the European Union, lung cancer had the highest economic cost (as high as €18.8 billion, or 15% of overall cancer costs) amongst all cancers in 2009 ([@b6-ol-0-0-7047]).

Although advances have been made in multidisciplinary treatments for lung cancer, this cancer continues to have a poor prognosis due to a general lack of symptoms until it reaches an advanced stage ([@b7-ol-0-0-7047]). Due to discrepancies between results within the same stage, there is an urgent demand for novel parameters, particularly serum predictive biomarkers, to combine with low-dose computed tomography, x-ray examination and other diagnostic tests to complement tumor-node-metastasis (TNM) staging ([@b8-ol-0-0-7047]) to accurately predict the prognosis and provide appropriate preoperative patient counseling ([@b9-ol-0-0-7047]). White blood cell (WBC) counts and WBC subtype counts are well established in systemic inflammatory or infection responses. Wculek and Malanchi hypothesized that an altered presence of leukocytes within distant tissues of tumor-bearing hosts may affect specific subsets of disseminating cancer cells ([@b10-ol-0-0-7047]). Notably, leukocytes were demonstrated to accumulate in the lung prior to infiltration of the tissue by cancer cells (in a pre-metastatic lung), and their numbers increased during metastatic progression (in a metastatic lung) ([@b10-ol-0-0-7047]). Increasingly, evidence has demonstrated that a systemic inflammatory response has a prognostic value in various cancers ([@b11-ol-0-0-7047]--[@b14-ol-0-0-7047]). Amongst the convenient and available markers, a high ratio of neutrophils to lymphocytes (NLR) and platelets to lymphocytes (PLR), which are calculated from the complete blood count with differential ([@b15-ol-0-0-7047]), also have been combined to form inflammation-based prognostic scores to predict cancer survival ([@b11-ol-0-0-7047]). As they are routine laboratory tests, the NLR and PLR are easy to obtain and may serve an important function in predicting the survival and monitoring of cancer progression in patients with lung cancer. Therefore, the present study aimed to explore the prognostic values of NLR and PLR in patients with lung cancer.

Materials and methods
=====================

### Study population

A retrospective analysis was performed on 695 patients diagnosed with lung cancer from high incidence areas in Hebei Province and treated at the Fourth Hospital of Hebei Medical University (Shijazhuang, China; also known as the Tumor Hospital of Hebei Province, a large and comprehensive hospital with the rank of level three and grade A) from January 1, 2000 to December 31, 2005. All the patients included were histologically confirmed to have lung cancer and received a routine laboratory examination at diagnosis. Patients with pulmonary hypertension and other severe diseases were excluded.

### Clinical data collection

Baseline characteristics were collected, including age, sex, occupation, family history, tumor data (pathological type, TNM stage and surgical situation), and laboratory data (hemoglobin levels, neutrophil count, lymphocyte count, and platelet count on the first hospitalized day). The NLR was defined as a simple ratio between the absolute neutrophil count and the absolute lymphocyte count; similarly, PLR was defined as the ratio of the absolute platelet count and the absolute lymphocyte count.

### Follow-up studies

The follow-up evaluations were conducted according to the standard follow-up system of the hospital, i.e., every 6 months after patients were discharged from the hospital. The deadline for follow-up evaluations was December 31, 2012. The survival period was measured from the date of admission to the date of mortality or the date of the follow-up deadline.

### Statistical analysis

SPSS 21.0 (IBM Corp., Armonk, NY, USA) and Microsoft Office Excel 2007 (Microsoft Corporation, Redmond, WA, USA) were used for statistical analysis. The optimal cutoff values for the NLR and the PLR were determined from the receiver operating curve (ROC) analysis. The comparison between high and low NLR and PLR groups used χ^2^ tests or the Fisher\'s exact probability method to explore the associations between the NLR and PLR and other clinicopathological variables. The Kaplan-Meier method for survival analysis was performed. The overall survival (OS) in different groups was identified using the log-rank test. P\<0.05 was considered to indicate a statistically significant difference. Univariate and multivariate Cox regression models were performed to analyze the factors that may influence the OS rate.

Results
=======

A total of 695 patients with lung cancer were included, of which 56 patients were still alive and 639 patients had succumbed, by the end of the follow-up. The follow-up rate was 98.44%. Overall, 510 (73.38%) cases were male, and 185 (26.62%) were female with an average age of 61.69±11.07 years (ranging between 20--89). In total, 232 (33.38%) patients underwent surgery.

The median absolute neutrophil count was 6.56×10^6^/ml (ranging between 0.01--87.00), the median absolute platelet count was 276.68×10^6^/ml (ranging between 6.00--716.00), and the median value of lymphocyte count was 1.89×10^6^/ml (ranging between 0.11--31.60). Then, ROC curves for OS were used to define the optimal cutoff of NLR and PLR; the results were 6.0 and 248, respectively. The sensitivity and specificity were 69.1 and 43.4%, and 55.7 and 49.9%, respectively.

The associations between the NLR and PLR and the baseline clinical characteristics of lung cancer patients were analyzed ([Tables I](#tI-ol-0-0-7047){ref-type="table"} and [II](#tII-ol-0-0-7047){ref-type="table"}). The clinical variables included age, sex, pathological type, TNM stage, surgery, metastasis, occupation, and family history. 501 patients, accounting for 72.09% of all patients, were placed into the low NLR group (NLR\<6.0), and 194 patients, accounting for 27.91% of all patients, were placed in the high NLR group. 549 patients, accounting for 78.99% of all patients, were placed into the low PLR group (PLR\<248.0), and 146 patients, accounting for 21.01% of all patients, were placed into in the high PLR group. The results revealed that there was no association between age, sex, pathological type, occupation, or family history incidence and NLR in different groups, but there was a statistically significant association between the TNM stage, surgery, metastasis incidence and NLR (P\<0.001). No associations between age, sex, pathological type, occupation, family history, or metastasis incidence and PLR was identified, but the association between PLR and both the TNM stage and surgery incidence was statistically significant (P\<0.001).

The association between NLR, PLR and the OS rate of lung cancer patients is presented in [Table III](#tIII-ol-0-0-7047){ref-type="table"}. The pathological type, TNM stage, surgery, metastasis, occupational status and NLR were demonstrated to affect the OS rate. The 1-, 3-, and 5-year OS rates of lung cancer patients in the low NLR group were 54.7, 28.9 and 20.9%, respectively, while those in the high NLR group were 43.6, 24.6 and 17.5%, respectively. Notably, patients in the low NLR group had a significantly longer OS than patients in the high NLR group (819.57 days vs. 629.86 days, P=0.041; [Fig. 1](#f1-ol-0-0-7047){ref-type="fig"}). However, there was no significant difference between patients in the low-PLR or high-PLR groups in terms of OS rates during the different follow-up periods (P=0.217; [Fig. 2](#f2-ol-0-0-7047){ref-type="fig"}). Furthermore, the potential prognostic factors for OS rates were explored by conducting univariate Cox regression analysis ([Table IV](#tIV-ol-0-0-7047){ref-type="table"}).

Discussion
==========

Lung cancer is one of the leading causes of mortality worldwide in the 21st century ([@b16-ol-0-0-7047]), with an equally high incidence between men and women, and between developed countries and less developed countries ([@b17-ol-0-0-7047]). The dramatic increase in the incidence of lung cancer over the last 40 years ([@b3-ol-0-0-7047]) established the rationale for developing biomarkers for the prognosis of lung cancer. This stems from the fact that, at the population level, the earlier a disease is predicted, the better the outcome and the lower the health care cost ([@b18-ol-0-0-7047]). Multiple studies have revealed that environmental and occupational causes, including genetic and sex-specific factors, nutrition, obesity, tobacco smoking, air pollution and, potentially, human papilloma virus infection, are involved in increasing the lung cancer burden ([@b19-ol-0-0-7047],[@b20-ol-0-0-7047]). The International Agency for Research on Cancer (IARC) has classified air pollution and particulate matter as carcinogenic to humans ([@b21-ol-0-0-7047],[@b22-ol-0-0-7047]). Although there have been significant advances in the diagnosis and comprehensive treatment of lung cancer, the majority of patients are diagnosed in the late stages of the disease, and the 5-year survival rate and quality of life of these patients remains low ([@b23-ol-0-0-7047]).

Multiple methods to diagnose and predict the survival of lung cancer have emerged, including pathological confirmation and tumor biomarkers, which include specific RNA, DNA, or the mutation/methylation of nucleic acids of cells and tissues ([@b24-ol-0-0-7047]--[@b27-ol-0-0-7047]). Another biomarker, circulating tumor DNA, offers an alternative, temporal and less-invasive option (termed a 'liquid biopsy' due to the biopsy sample being plasma) for accurate early detection with high sensitivity for patients with lung cancer ([@b28-ol-0-0-7047]). However, the above approaches also have disadvantages. It is always difficult to obtain tumor samples; and, in certain tumors, the tissues are only accessible through fine-needle aspirates, particularly in early stage cases, and the acquisition of samples from different medical centers is challenging or time-consuming particularly as they take a long time to recover. However, NLR and PLR have now been evaluated for use as prognostic factors, and are simple, convenient, damage-free and supplementary to the plethora of biomarkers and other ways with which to predict the survival of patients with tumors.

Inflammation is a physiological process that is a crucial function of the innate immune system, as it is a response to acute or chronic tissue damage, whether resulting from physical injury, ischemic injury, infection, exposure to toxins, or other types of trauma. When these situations occur within the body, the immune system will cause neutrophils, leukocytes, lymphocytes and other inflammatory cells to be activated and then be attracted to the site of damage ([@b29-ol-0-0-7047]). Currently. there is increasing recognition of the involvement of immune cells and their supporting pro-inflammatory mediators, typically associated with the containment of an inflammatory process, in the pathobiology of multiple types of cancer, including gastrointestinal, liver and breast cancer ([@b30-ol-0-0-7047]--[@b32-ol-0-0-7047]). They may be involved in tumor suppression by stimulating an antitumor immune response, but more often, and under certain conditions, this response appears to stimulate tumor development ([@b29-ol-0-0-7047]). Bollrath *et al* ([@b33-ol-0-0-7047]) discovered that the tumor microenvironment is comprised not only of tumor cells but also of stromal cells (including fibroblasts and endothelial cells), cells from the innate immune system (including macrophages, neutrophils, mast cells, myeloid-derived suppressor cells, dendritic cells and natural killer cells) and the adaptive immune cells, T and B lymphocytes.

Previous studies have begun to unravel the mechanisms linking the host inflammatory response to tumor growth, invasion and metastasis in cancers. Based on this relationship between inflammation and cancer progression, several inflammation-based scores have been demonstrated to have prognostic value in numerous types of malignant solid tumor ([@b34-ol-0-0-7047]), including lung ([@b35-ol-0-0-7047]) and liver cancer ([@b36-ol-0-0-7047]). Accumulating evidence has indicated that long term inflammation-associated factors activate the occurrence and metastasis of certain types of cancer, as systemic inflammatory responses and blood NLR, and local inflammatory responses (including the infiltration of various immune cells and their subsets in tumors) are associated with the prognosis of cancer ([@b37-ol-0-0-7047]). Certain studies have revealed that the human lung cancer stroma is composed of immune and inflammatory cells ([@b38-ol-0-0-7047],[@b39-ol-0-0-7047]). These studies demonstrated that, in human lung cancer sections, there was a significant elevation/infiltration of total-T lymphocytes (CD3^+^, 8^+^, 4^+^, 20^+^ etc.) and tumor-infiltrating lymphocytes compared with in healthy donor specimens. All these immune cell markers were observed in different types of lung cancer, and the tumor-infiltrating lymphocytes were more frequent in poorly differentiated tumors and tumors with microscopic vascular invasion.

In the present study, it was discovered that the patients with lung cancer from the low NLR group had a lower OS rate than patients in the high NLR group, which is in accordance with results observed in other types of cancers ([@b40-ol-0-0-7047],[@b41-ol-0-0-7047]). Abbasciano *et al* ([@b42-ol-0-0-7047]) hypothesized that the activation and fibrinolysis of platelets may trigger colon cancer. The physiological immune response of circulating leukocytes to various abnormal events is characterized by an increased neutrophil count and decreased lymphocyte count, which results in high NLR and PLR levels ([@b43-ol-0-0-7047]). When the infection or inflammatory response develops into a chronic disease, the opportunity for tumorigenesis will increase ([@b44-ol-0-0-7047]). Mediators of chronic inflammation inevitably contribute to tumor initiation, development and progression. As a consequence, upregulation and overexpression of these molecular mediators often serve as a prognostic marker for patients with cancer ([@b32-ol-0-0-7047]). Chronic inflammation predisposes and potentially initiates cancer in the host by inducing DNA damage, chromosomal instability, and the production of chemokines, cytokines and growth factors at the inflammatory sites ([@b45-ol-0-0-7047],[@b46-ol-0-0-7047]). When a tumor exists in the body, tumor necrosis factors, including interleukin (IL)-1 and IL-6, will contribute to progression towards malignancy ([@b47-ol-0-0-7047]). Meanwhile, systemic inflammatory responses towards a tumor may also increase metastasis through the inhibition of apoptosis and augmentation of angiogenesis ([@b48-ol-0-0-7047]). Neutrophils secrete vascular endothelial growth factor in addition to a pro-angiogenic factor that is involved in tumor development, which is an absolute requirement in tumor growth and metastatic disease ([@b49-ol-0-0-7047]). Therefore, the high level of NLR may serve a function in predicting the survival of patients with lung cancer.

As there is a high level of specificity of etiology and pathogenicity in high risk areas of lung cancer, the relationship between NLR, PLR and the prognosis of patients with lung cancer was first proposed relating to the Hebei province ([@b9-ol-0-0-7047]), one of the high risk areas in China, where there was a demonstrable increase in the lung cancer incidence rate from 1973 to 2011. In 2011, the crude lung cancer incidence rate in the registry areas was 45.44/100,000, accounting for 18.44% of all cancers ([@b3-ol-0-0-7047]). Comparing the results of the present study with Globocan 2012 data ([@b50-ol-0-0-7047]), the lung cancer incidence in Hebei Province in 2011 (ASRW=39.01/100,000) was 1.08 times that of China as a whole (36.1/100,000) and 1.69 times that of global rates (23.1/100,000). The potential association with large-scale samples was explored in the present study, which was consistent with results in esophageal cancer ([@b9-ol-0-0-7047]). The present study also illustrated that the OS rate of patients with lung cancer with a high NLR level who live in high-risk areas is lower than those with a low NLR level. Hence, the NLR may be a promising approach for predicting the OS rate of lung cancer patients from a high-risk area.

However, although there is a similar mechanism in both PLR and NLR, no potential relationship between PLR and the survival of patients with lung cancer was identified.

Although there is increasing proof that the NLR and the PLR may be used as prognostic factors in lung cancer, the mechanisms remain unknown. Further studies are required to confirm these results and transition these methods from being largely investigational to potentially being used routinely in lung cancer prognosis.
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###### 

Associations between NLR and patient characteristics.

  Factor                    Low NLR (n=501)   High NLR (n=194)   χ2        P-value
  ------------------------- ----------------- ------------------ --------- ---------
  Age, years                61.69±11.07                                    
  Sex                                                            0.744     0.388
    Male                    373               137                          
    Female                  127                 58                         
  Age, years                                                     3.312     0.069
    \<40                    26                    4                        
    ≥40                     475               190                          
  Pathological type                                              2.290     0.130
    Small cell cancer       46                  12                         
    Non-small cell cancer   455               182                          
  TNM stage                                                      20.041    0.000
    I                       83                    9                        
    II                      158                 70                         
    III                     176                 68                         
    IV                      84                  47                         
  Surgery                                                        41.118    0.000
    Yes                     203                 29                         
    No                      298               165                          
  Metastasis                                                     172.154   0.000
    Yes                     220               191                          
    No                      281                   3                        
  Occupation                                                     0.061     0.804
    Labourer                204                 77                         
    Others                  297               117                          
  Family history                                                 0.688     0.407
    Yes                     37                  18                         
    No                      464               176                          

NLR, neutrophil-to-lymphocyte ratio; TNM, tumor-node-metastasis.

###### 

Associations between PLR and patient characteristics.

  Factor                    Low PLR (n=549)   High PLR (n=146)   χ^2^     P-value
  ------------------------- ----------------- ------------------ -------- ---------
  Age, years                61.69±11.07                                   
  Sex                                                            2.261    0.133
    Male                    410               100                         
    Female                  139                 46                        
  Age, years                                                     0.019    0.890
    \<40                    24                    6                       
    ≥40                     525               140                         
  Pathological type                                              1.985    0.159
    Small cell cancer       50                    8                       
    Non-small cell cancer   499               138                         
  TNM stage                                                      51.371   0.000
    I                       84                    7                       
    II                      151                 77                        
    III                     219                 26                        
    IV                      95                  36                        
  Surgery                                                        21.969   0.000
    Yes                     207                 25                        
    No                      342               121                         
  Metastasis                                                     2.106    0.147
    Yes                     317                 94                        
    No                      232                 52                        
  Occupation                                                     0.600    0.439
    Labourer                223                 58                        
    Others                  326                 88                        
  Family history                                                 1.413    0.235
    Yes                     40                  15                        
    No                      509               131                         

PLR, platelet-to-lymphocyte ration; TNM, tumor-node-metastasis.

###### 

Prognostic factors according to the univariate analysis.

                                  OS Rate (%)                          
  ------------------------- ----- ------------- ------ ------ -------- -------
  Sex                                                         0.234    0.628
    Male                    510   84.6          28.7   19.7            
    Female                  185   78.9          25.4   21.1            
  Age, years                                                  1.735    0.188
    \<40                    30    55.7          40.0   33.3            
    ≥40                     665   51.9          27.3   19.6            
  Pathological type                                           8.494    0.004
    Small cell cancer       58    71.1          36.3   33.6            
    Non-small cell cancer   637   50.0          27.1   18.9            
  TNM stage                                                   69.095   0.000
    I                       92    83.7          66.3   52.2            
    II                      228   50.2          24.9   19.1            
    III                     245   50.8          22.2   14.0            
    IV                      130   36.2          16.7   9.1             
  Surgery                                                     65.848   0.000
    Yes                     232   70.3          46.0   35.6            
    No                      463   43.0          18.5   12.1            
  Metastasis                                                  60.599   0.000
    Yes                     411   43.7          17.6   10.4            
    No                      284   63.4          42.4   33.8            
  Occupation                                                  6.099    0.014
    Labourer                281   57.7          31.3   23.5            
    Others                  414   48.2          25.5   17.8            
  Family history                                              0.002    0.968
    Yes                     55    55.2          24.7   16.6            
    No                      640   51.9          28.2   20.3            
  NLR                                                         4.159    0.041
    Low                     501   54.7          28.9   20.9            
    High                    194   43.6          24.6   17.5            
  PLR                                                         1.523    0.217
    Low                     549   52.9          28.5   21.0            
    High                    146   47.4          25.6   16.7            

TNM, tumor-node-metastasis; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.

###### 

Prognostic factors according to multivariate analysis.

  Factor              β        SE      Wald     RR (95% CI)            P-value
  ------------------- -------- ------- -------- ---------------------- ---------
  Pathological type   0.476    0.166   8.241    1.069 (1.162--2.227)   0.004
  Surgery             −0.730   0.093   61.273   0.482 (0.401--0.579)   0.000
  Metastasis          0.673    0.089   57.536   1.960 (1.647--2.332)   0.000
  TNM Stage I                                   1.00                   
  TNM Stage II        0.384    0.176   4.790    1.469 (1.041--2.072)   0.029
  TNM Stage III       0.269    0.102   6.800    1.310 (1.071--1.603)   0.009
  TNM Stage IV        0.509    0.104   24.212   1.661 (1.355--2.038)   0.000
  NLR                 0.187    0.093   4.071    1.205 (1.005--1.445)   0.044
  PLR                 0.122    0.100   1.494    1.130 (0.929--1.373)   0.222

TNM, tumor-node-metastasis; NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio; SE, standard error; RR, relative risk; CI, confidence interval.
